Introduction
Dominik Müller and his group work at the Max-Delbrueck Center for Molecular Medicine (MDC) in Berlin, Germany. The group's major interest is related to the renin-angiotensin system (RAS) and to hypertension/angiotensin (Ang) II-induced target organ damage. Dominik Müller together with Michael Bader (MDC), Genevieve Nguyen (INSERM U36, Paris, France), and Jan Danser (Erasmus, Rotterdam, The Netherlands) have initiated a major effort to elucidate the role of the putative (pro)renin receptor in cardiovascular disease. 1 Together with Ruth Schmidt-Ullrich and Claus Scheidereit (MDC, Berlin), the group showed that NF-κB plays a decisive role in vascular endothelial cells in terms of mediating target organ damage in the kidney and heart. They used a novel knock-in mouse model that expressed a dominant-negative construct. The workhorse of the laboratory has been a double- 
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Renin transgenic rat (dTGR) strain expressing both human renin and angiotensinogen genes. The group showed that the early death of these animals is related to fatal arrhythmias. A cardiac magnetic field mapping approach may elucidate the origin of rhythm disturbances in this model. The same model was used to elucidate the role of p38 MAP kinase signalling in terms of target organ damage. In terms of elucidating susceptibility to target organ damage the group is also pursuing the role of innate and acquired immunity. Finally, the Müller group also participated in elucidating the effects of glucocorticoids in mediating vascular cell function that could contribute to the metabolic syndrome and its consequences.
The (pro)renin receptor and its significance
The recently cloned (pro)renin/renin receptor is an exciting new addition to the RAS (figure 1). However, aside from the nonproteolytic activation of prorenin and evidence that the (pro)renin receptor activates extracellular-related kinase (ERK), its role in mediating target organ damage is unclear. Recently, we began to analyse the role of the prorenin receptor. We recently tested whether human prorenin and renin induce ERK half activation and whether the direct renin inhibitor (DRI) aliskiren influences the receptor. Uncontrolled prorenin/receptor system activation, independent of Ang II generation, might play a role in the pathogenesis of cardiovascular and renal dysfunction in vivo. Therefore, it is tempting to speculate that prorenin plays a direct pathogenic role in target organ damage. To specifically block the (pro)renin receptor and evaluate its role on end-organ damage, we will generate various animal models with modified prorenin levels and/or (pro)renin/renin receptor expression. Furthermore, we are going to test potential (pro)renin/renin receptor inhibitors for their therapeutic utility.
Role of the renin-angiotensinaldosterone system in AngII/ hypertension-induced target organ damage
The first direct DRI, aliskiren, is now available to treat hypertension in humans. We contributed to the preclinical development of human DRIs. The compounds could only be tested in primates, since the renins are species-specific. The dTGR harbours both human renin and angiotensinogen genes, and thus provides an ideal animal model. Aliskiren eliminated hypertension and organ damage in the dTGR model. Vascular smooth muscle cells (SMC) isolated from dTGRs exhibited a synthetic phenotype in that they grew faster and react differently in response to stimuli compared to wild-type SMC. One interesting finding involved the production of complement by the cells in response to tumor necrosis factorα (TNF-α) and C-reactive protein. The dTGR model showed strong evidence for complement. These observations demonstrate the role of innate immune mechanisms that were previously not appreciated. Two new aspects of the RAS were recently investigated. We showed that Ang II sets a process in motion that results in complement expression and eventually, membrane attack complex (C5-C9) activation. 2 We focused on aldosterone signalling in vascular cells 3 and in transgenic animals. 4
The immune system, NF-κ κB in vascular cells and target organs
Hypertension-induced target organ damage is not generally regarded as an immunological disease. However, we have shown that inflammation (innate immunity) plays a role in the pathogenesis. Our understanding concerning adaptive immunity is rather rudimental. Nevertheless, there is growing evidence that an over-activated immune system also plays a role in non-immune hypertension-induced cardiovascular disease. NF-κB participates in hypertensioninduced vascular and target organ damage. We tested whether or not endothelial cell-specific NF-κB suppression would be ameliorative. We investigated Cre/lox transgenic mice with endothelial cell-restricted NF-κB super-repressor IκBαΔN (Tie-1-ΔN mice) over-expression. The surprising finding is that endothelial-specific NF-κB suppression suffices to ameliorate hypertension-induced renal damage (figure 2). The results demonstrate that inhibition of NF-κB signalling in a single cell type is able to reduce renal tubular, vascular, and to a lesser extent also glomerular damage. Endothelial NF-κB inhibition did not affect the development of hypertension indicating that the renal protection was blood pressure (BP)-independent. 5
Sudden death is "nature's way" of slowing us down
Together with Ralf Dechend and Robert Fischer (Cardiology, Franz-Volhard Clinic, and HELIOS Klinikum Berlin-Buch and Experimental and Clinical Research Center, Berlin, Germany), we investigated whether or not p38 mitogenactivated protein kinase inhibition (p38i) ameliorates Ang II-induced target organ damage and improves sudden death in the dTGR. Systolic BP of untreated dTGR was > 200 mmHg, but partially reduced after p38i treatment. Cardiac hypertrophy index was unchanged in untreated and p38i-treated dTGR. The β-myosin heavy chain expression of p38i-treated hearts was
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Renin Report P38i treatment significantly reduced cardiac fibrosis, connective tissue growth factor, TNF-α, interleukin-6, and macrophage infiltration. At week eight, mortality of untreated dTGR was 100%, but was reduced to 10% in the p38i group. Cardiac magnetic field mapping showed prolongation of depolarisation and repolarisation in untreated dTGR with a partial reduction by p38i. Programmed electrical stimulation elicited ventricular tachycardias in 81% of untreated dTGR, but only in 48% p38i-treated dTGR. In conclusion, p38i prevented dTGR from slowing down, improved survival, target organ damage, and arrhythmogenic potential in Ang II-induced target organ damage. 6
Renin Academy in Focus
Renin Academy presence at major congresses
European Society of Hypertension
It was standing room only at the second Topical Workshop hosted by the Renin Academy on 16 June this year at the European Society of Hypertension meeting in Milan. The Workshop was titled 'unlocking the mysteries of the renin system' and was chaired by Thomas Unger (Institute of Pharmacology, Universitat zu Kiel, Kiel, Germany) and Luis Ruilope (Hospital 12 de Octubre, Madrid, Spain). The 90-minute workshop held the attention of more than 1,000 people with many more hoping to hear the discussions as they stood in the hall outside the auditorium. The main focus of the session was to develop our knowledge of the benefits of improved renin system control, as well as reviewing some of the latest research on renin and the (pro)renin receptor.
Michel Azizi (Université Paris Descartes, Faculté de Médecine, Paris, France) focused the first presentation on the clinical benefits of renin system blockade. He demonstrated the role of renin system blockers in achieving maximal protection from organ damage using high doses of angiotension converting-enzyme inhibitors (ACEinhibitors) or angiotensin receptor blockers (ARBs) above those normally used in clinical practice as well as a combination of ACE-inhibitors and ARBs. Norman Hollenberg (Brigham and Women's Hospital and Harvard Medical Center, Boston, USA) shared some recent aliskiren data demonstrating an improvement in renal plasma flow beyond levels achieved with ACE-inhibitors and ARBs, and considered how this may translate into clinical practice. Hollenberg also provided a brief summary of the evidence for non-renin and ACE pathways for angiotensin II generation. Friedrich Luft (Nephrology/ Hypertension Section Medical Faculty of the Charité and the Franz Volhard Clinic, HELIOS Klinikum-Berlin, Germany) reviewed the pre-clinical data available to-date with aliskiren, the first approved direct renin inhibitor (DRI). In the animal models used, aliksiren lowered blood pressure and demonstrated reno-protectve, cardioprotective and vasculo-protective effects. He also presented some interesting early data on the renal localisation of aliskiren and postulated how this may add to organ protection above and beyond that of the ACE-inhibitors and ARBs. The Workshop was concluded with a presentation from Thomas Unger in which he reviewed the recent evidence of the importance of renin and (prorenin control in human physiology and pathophysiology.
Further Renin Academy events in 2007
The Renin Academy has been involved in a number of major international congresses this year and has two additional congresses activities before the end 
